T he renin-angiotensin system (RAS) plays a key role in blood pressure regulation, fluid and electrolyte balance, cellular growth, thirst, and cardiac/renal function. The classic system primarily involves 2 enzymes: renin, which cleaves angiotensinogen to the inactive decapeptide angiotensin (Ang) I; and Ang-converting enzyme (ACE), a dipeptidyl carboxypeptidase that hydrolyzes Ang I to the octapeptide Ang II. The elucidation of the ACE pathway in parallel with potent and selective ACE inhibitors is clearly a pivotal achievement in our understanding of the RAS and in attaining effective therapies for hypertension and end organ damage. Indeed, ACE inhibitors attenuate Ang II formation and augment the levels of the heptapeptide Ang (1-7), a peptide that counterbalances the actions of Ang II on blood pressure and cellular growth through a unique receptor system. Ang II mediates the majority of its actions at the Ang II type 1 (AT 1 ) receptor, including the stimulation of vasoconstriction, sodium retention, cellular growth, and oxidative stress, whereas recent studies show that Ang (1-7) at the AT 1-7 or mas receptor and Ang II via the AT 2 receptor subtype counterregulate the actions of Ang II at the AT 1 receptor.